20+
FDA PK/PD Phase I & II hematology reviews
10+
Phase I & II hematology studies designed
D2V Clinical possesses exceptional expertise and extensive hands-on experience in the field of hematology development. With a profound understanding of diverse patient populations, we are uniquely positioned to provide valuable support to our sponsors and research investigators, facilitating the acceleration of market approvals for their hematology compounds.
Our dedicated team of experts offers a combination of scientific prowess, regulatory acumen, and operational excellence to deliver comprehensive and effective solutions that drive success in the development of hematology treatments.
Early-phase hematology expertise
We offer expert guidance in selecting optimal patient populations, identifying key biomarkers, and harnessing cutting-edge technologies to maximize the success of your hematology trials. With our agile approach, we ensure swift patient enrollment, meticulous data collection, and insightful analysis, propelling rapid advancements in hematology therapies.
Hematologic malignancies experience
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Chronic myeloid leukemia
- Diffuse large b-cell lymphoma
- Hodgkin’s disease
- Leukemia
- Multiple myeloma
- Myelofibrosis
- Non-Hodgkin’s lymphoma
Partnering with D2V Clinical unlocks a realm of robust experience and tailored solutions designed exclusively for early-phase hematology research.
Our team of experts closely collaborates with clients to:
Develop comprehensive trial strategies
Optimize study designs
